vs
Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and HANMI FINANCIAL CORP (HAFC). Click either name above to swap in a different company.
4D Molecular Therapeutics, Inc. is the larger business by last-quarter revenue ($85.1M vs $71.2M, roughly 1.2× HANMI FINANCIAL CORP). HANMI FINANCIAL CORP runs the higher net margin — 29.8% vs 22.8%, a 7.0% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs 17.1%). HANMI FINANCIAL CORP produced more free cash flow last quarter ($203.7M vs $28.5M). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 10.4%).
4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.
Hanmi Bank Corporation is a community bank headquartered in Los Angeles, California, with 35 branches and eight loan production offices in California, Texas, Illinois, New York, New Jersey and Virginia.
FDMT vs HAFC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $85.1M | $71.2M |
| Net Profit | $19.4M | $21.2M |
| Gross Margin | — | — |
| Operating Margin | 17.3% | 29.8% |
| Net Margin | 22.8% | 29.8% |
| Revenue YoY | 8508900.0% | 17.1% |
| Net Profit YoY | 139.1% | 20.0% |
| EPS (diluted) | $0.43 | $0.70 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $85.1M | $71.2M | ||
| Q3 25 | $90.0K | $71.0M | ||
| Q2 25 | $15.0K | $65.2M | ||
| Q1 25 | $14.0K | $62.8M | ||
| Q4 24 | $1.0K | $60.8M | ||
| Q3 24 | $3.0K | $58.5M | ||
| Q2 24 | $5.0K | $56.7M | ||
| Q1 24 | $28.0K | $58.4M |
| Q4 25 | $19.4M | $21.2M | ||
| Q3 25 | $-56.9M | $22.1M | ||
| Q2 25 | $-54.7M | $15.1M | ||
| Q1 25 | $-48.0M | $17.7M | ||
| Q4 24 | — | $17.7M | ||
| Q3 24 | $-43.8M | $14.9M | ||
| Q2 24 | $-35.0M | $14.5M | ||
| Q1 24 | $-32.4M | $15.2M |
| Q4 25 | 17.3% | 29.8% | ||
| Q3 25 | -67983.3% | 31.1% | ||
| Q2 25 | -396373.3% | 23.2% | ||
| Q1 25 | -383007.1% | 28.1% | ||
| Q4 24 | — | 29.1% | ||
| Q3 24 | -1704400.0% | 25.5% | ||
| Q2 24 | -849120.0% | 25.5% | ||
| Q1 24 | -136200.0% | 26.0% |
| Q4 25 | 22.8% | 29.8% | ||
| Q3 25 | -63195.6% | 31.1% | ||
| Q2 25 | -364386.7% | 23.2% | ||
| Q1 25 | -342657.1% | 28.1% | ||
| Q4 24 | — | 29.1% | ||
| Q3 24 | -1461433.3% | 25.5% | ||
| Q2 24 | -699060.0% | 25.5% | ||
| Q1 24 | -115717.9% | 26.0% |
| Q4 25 | $0.43 | $0.70 | ||
| Q3 25 | $-1.01 | $0.73 | ||
| Q2 25 | $-0.98 | $0.50 | ||
| Q1 25 | $-0.86 | $0.58 | ||
| Q4 24 | — | $0.58 | ||
| Q3 24 | $-0.79 | $0.49 | ||
| Q2 24 | $-0.63 | $0.48 | ||
| Q1 24 | $-0.66 | $0.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $402.7M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $505.7M | $796.4M |
| Total Assets | $566.7M | $7.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $402.7M | — | ||
| Q3 25 | $305.1M | — | ||
| Q2 25 | $293.2M | — | ||
| Q1 25 | $321.4M | — | ||
| Q4 24 | $424.9M | — | ||
| Q3 24 | $501.9M | — | ||
| Q2 24 | $541.9M | — | ||
| Q1 24 | $525.9M | — |
| Q4 25 | $505.7M | $796.4M | ||
| Q3 25 | $369.0M | $779.5M | ||
| Q2 25 | $420.9M | $762.8M | ||
| Q1 25 | $469.7M | $751.5M | ||
| Q4 24 | $510.6M | $732.2M | ||
| Q3 24 | $552.9M | $736.7M | ||
| Q2 24 | $588.3M | $707.1M | ||
| Q1 24 | $600.6M | $703.1M |
| Q4 25 | $566.7M | $7.9B | ||
| Q3 25 | $424.0M | $7.9B | ||
| Q2 25 | $473.6M | $7.9B | ||
| Q1 25 | $515.7M | $7.7B | ||
| Q4 24 | $560.4M | $7.7B | ||
| Q3 24 | $604.0M | $7.7B | ||
| Q2 24 | $620.1M | $7.6B | ||
| Q1 24 | $629.9M | $7.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.6M | $206.0M |
| Free Cash FlowOCF − Capex | $28.5M | $203.7M |
| FCF MarginFCF / Revenue | 33.5% | 286.2% |
| Capex IntensityCapex / Revenue | 0.1% | 3.2% |
| Cash ConversionOCF / Net Profit | 1.47× | 9.70× |
| TTM Free Cash FlowTrailing 4 quarters | $-109.9M | $356.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.6M | $206.0M | ||
| Q3 25 | $-46.5M | $146.9M | ||
| Q2 25 | $-43.4M | $-19.0M | ||
| Q1 25 | $-47.8M | $25.8M | ||
| Q4 24 | $-134.6M | $52.6M | ||
| Q3 24 | $-29.4M | $6.7M | ||
| Q2 24 | $-30.2M | $2.1M | ||
| Q1 24 | $-29.1M | $30.0M |
| Q4 25 | $28.5M | $203.7M | ||
| Q3 25 | $-46.6M | $146.4M | ||
| Q2 25 | $-43.4M | $-19.6M | ||
| Q1 25 | $-48.4M | $25.6M | ||
| Q4 24 | $-138.4M | $49.9M | ||
| Q3 24 | $-31.2M | $6.5M | ||
| Q2 24 | $-30.6M | $1.3M | ||
| Q1 24 | $-29.8M | $29.2M |
| Q4 25 | 33.5% | 286.2% | ||
| Q3 25 | -51765.6% | 206.3% | ||
| Q2 25 | -289620.0% | -30.0% | ||
| Q1 25 | -345635.7% | 40.7% | ||
| Q4 24 | -13837100.0% | 82.1% | ||
| Q3 24 | -1038966.7% | 11.1% | ||
| Q2 24 | -611840.0% | 2.3% | ||
| Q1 24 | -106421.4% | 50.0% |
| Q4 25 | 0.1% | 3.2% | ||
| Q3 25 | 101.1% | 0.8% | ||
| Q2 25 | 440.0% | 0.9% | ||
| Q1 25 | 4507.1% | 0.4% | ||
| Q4 24 | 378600.0% | 4.3% | ||
| Q3 24 | 59266.7% | 0.4% | ||
| Q2 24 | 6980.0% | 1.4% | ||
| Q1 24 | 2535.7% | 1.4% |
| Q4 25 | 1.47× | 9.70× | ||
| Q3 25 | — | 6.66× | ||
| Q2 25 | — | -1.26× | ||
| Q1 25 | — | 1.46× | ||
| Q4 24 | — | 2.97× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | — | 1.98× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
